-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RI5275VjTvoQey8++LKDiup3etSrqMVj/du/jzkMIYv6sbK36VnNr6kwww77/XHx W89XBLnc3KC2Nzo+EsFbFQ== 0000936392-97-000145.txt : 19970222 0000936392-97-000145.hdr.sgml : 19970222 ACCESSION NUMBER: 0000936392-97-000145 CONFORMED SUBMISSION TYPE: S-1MEF PUBLIC DOCUMENT COUNT: 2 333-17657 FILED AS OF DATE: 19970211 EFFECTIVENESS DATE: 19970211 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSITE DIAGNOSTICS INC CENTRAL INDEX KEY: 0000834306 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330288606 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1MEF SEC ACT: 1933 Act SEC FILE NUMBER: 333-21607 FILM NUMBER: 97525555 BUSINESS ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194554808 MAIL ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 S-1MEF 1 FORM S-1 1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 11, 1997 REGISTRATION NO. 333- - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ BIOSITE DIAGNOSTICS INCORPORATED (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 3826 33-0288606 (STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER IDENTIFICATION NO.) INCORPORATION OR ORGANIZATION CLASSIFICATION CODE NUMBER)
11030 ROSELLE STREET, SAN DIEGO, CALIFORNIA 92121 (619) 455-4808 (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) ------------------------ KIM D. BLICKENSTAFF PRESIDENT AND CHIEF EXECUTIVE OFFICER BIOSITE DIAGNOSTICS INCORPORATED 11030 ROSELLE STREET SAN DIEGO, CALIFORNIA 92121 (619) 455-4808 (NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE OF PROCESS) ------------------------ COPIES TO: THOMAS E. SPARKS, JR., ESQ. ALAN C. MENDELSON, ESQ. JOHN L. DONAHUE, ESQ. D. BRADLEY PECK, ESQ. GEORGE A. GUCKER, ESQ. NANCY E. DENYES, ESQ. PILLSBURY MADISON & SUTRO LLP COOLEY GODWARD LLP P.O. BOX 7880 4365 EXECUTIVE DRIVE, SUITE 1100 SAN FRANCISCO, CA 94120-7880 SAN DIEGO, CA 92121-2128
------------------------ APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as practicable after this Registration Statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. [ ] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [X] 333-17657 If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] ------------------------ CALCULATION OF REGISTRATION FEE - ---------------------------------------------------------------------------------------------------------- - ---------------------------------------------------------------------------------------------------------- PROPOSED PROPOSED MAXIMUM MAXIMUM TITLE OF EACH CLASS OF SECURITIES AMOUNT TO BE OFFERING PRICE AGGREGATE AMOUNT OF TO BE REGISTERED REGISTERED(1) PER SHARE(2) OFFERING PRICE(2) REGISTRATION FEE - ---------------------------------------------------------------------------------------------------------- Common Stock, $.01 par value...... 460,000 shares $12.00 $5,520,000 $1,673 - ---------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------
(1) Includes 60,000 shares that the Underwriters have the option to purchase to cover over-allotments, if any. (2) Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(a). - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- 2 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE This Registration Statement is filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Act") by Biosite Diagnostics Incorporated (the "Company"), pursuant to Rule 462(b) under the Act. This Registration Statement incorporates by reference the contents of the Registration Statement on Form S-1 (File No. 333-17657) relating to the offering of up to 2,300,000 shares of Common Stock of the Company. CERTIFICATION The Company hereby certifies to the Commission that (i) it has instructed its bank to pay the Commission the filing fee set forth on the cover page of this Registration Statement by a wire transfer of such amount to the Commission's account at Mellon Bank as soon as practicable (but no later than the close of business on February 12, 1997), (ii) it will not revoke such instructions, (iii) it has sufficient funds in the relevant account to cover the amount of such filing fee, and (iv) it will confirm receipt of such instructions by the bank during regular business hours on February 12, 1997. 2 3 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 11, 1997. BIOSITE DIAGNOSTICS INCORPORATED By: /s/ Christopher J. Twomey ------------------------------------ Christopher J. Twomey Vice President, Finance and Chief Financial Officer
NAME TITLE DATE - ----------------------------------------------- ------------------------- ------------------ /s/ Kim D. Blickenstaff* President, Chief February 11, 1997 - ----------------------------------------------- Executive Officer Kim D. Blickenstaff (Principal Executive Officer) and Director /s/ Christopher J. Twomey Vice President and Chief February 11, 1997 - ----------------------------------------------- Financial Officer Christopher J. Twomey (Principal Financial Officer and Accounting Officer) /s/ Timothy J. Wollaeger* Chairman of the Board February 11, 1997 - ----------------------------------------------- Timothy J. Wollaeger /s/ Gunars E. Valkirs, Ph.D.* Director February 11, 1997 - ----------------------------------------------- Gunars E. Valkirs, Ph.D. /s/ Thomas H. Adams, Ph.D.* Director February 11, 1997 - ----------------------------------------------- Thomas H. Adams /s/ Howard E. Greene, Jr.* Director February 11, 1997 - ----------------------------------------------- Howard E. Greene /s/ Frederick J. Dotzler* Director February 11, 1997 - ----------------------------------------------- Frederick J. Dotzler* /s/ Stephen K. Reidy* Director February 11, 1997 - ----------------------------------------------- Stephen K. Reidy* /s/ Jesse I. Treu, Ph.D.* Director February 11, 1997 - ----------------------------------------------- Jesse I. Treu, Ph.D. *By: /s/ Christopher J. Twomey - ----------------------------------------------- Christopher J. Twomey Attorney-in-Fact
3 4 EXHIBIT INDEX
EXHIBIT SEQUENTIALLY NUMBER DESCRIPTION OF DOCUMENT NUMBERED PAGE - ------ ----------------------------------------------------------------------- ------------- 5.1 Opinion of Pillsbury Madison & Sutro LLP (incorporated by reference to Exhibit 5.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-17657)) 23.1 Consent of Ernst & Young LLP, Independent Auditors 23.2 Consent of Pillsbury Madison & Sutro LLP (included in its opinion incorporated by reference to Exhibit 5.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-17657))
EX-23.1 2 EXHIBIT 23.1 1 EXHIBIT 23.1 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS We consent to the reference to our firm under the captions "Experts" and "Selected Financial Data" and to the use of our report dated November 12, 1996, except for Note 7, as to which the date is December 5, 1996, included in Amendment No. 5 to Registration Statement (Form S-1 No. 333-17657) and related Prospectus of Biosite Diagnosis Incorporated for the registration of 460,000 shares of its common stock. /s/ ERNST & YOUNG LLP ERNST & YOUNG LLP San Diego, California February 11, 1997 -----END PRIVACY-ENHANCED MESSAGE-----